Clinical Trial Update: Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing CHOP versus fractionated ICED in transplant-eligible, untreated peripheral T-cell lymphoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
• ICED (fractionated)

Snippet

Sponsor: Samsung Medical Center | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: UNKNOWN